Stuart C. Gordon

41.2k total citations · 8 hit papers
359 papers, 21.8k citations indexed

About

Stuart C. Gordon is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Stuart C. Gordon has authored 359 papers receiving a total of 21.8k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Hepatology, 216 papers in Epidemiology and 42 papers in Infectious Diseases. Recurrent topics in Stuart C. Gordon's work include Hepatitis C virus research (200 papers), Liver Disease Diagnosis and Treatment (179 papers) and Hepatitis B Virus Studies (119 papers). Stuart C. Gordon is often cited by papers focused on Hepatitis C virus research (200 papers), Liver Disease Diagnosis and Treatment (179 papers) and Hepatitis B Virus Studies (119 papers). Stuart C. Gordon collaborates with scholars based in United States, France and United Kingdom. Stuart C. Gordon's co-authors include Janice K. Albrecht, John G. McHutchison, Mitchell L. Shiffman, Zachary Goodman, Vinod K. Rustgi, Kenneth Koury, Robert Reindollar, Michael P. Manns, Eugene R. Schiff and William M. Lee and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Stuart C. Gordon

340 papers receiving 21.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2001 4.8k citations Michael P. Manns, John G. McHutchison et al. profile →
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

1998 2.8k citations John G. McHutchison, Stuart C. Gordon et al. profile →
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

2011 1.2k citations Bruce R. Bacon, Stuart C. Gordon et al. profile →
Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

1998 1.1k citations Rafael Esteban, Vinod K. Rustgi et al. profile →
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 803 citations John G. McHutchison, Stuart C. Gordon et al. profile →
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2010 515 citations Paul Y. Kwo, Eric Lawitz et al. profile →
A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C

2001 507 citations Stuart C. Gordon, Eugene R. Schiff et al. Hepatology profile →
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

2014 421 citations Keith D. Lindor, Stuart C. Gordon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart C. Gordon United States	59	18.4k	16.6k	2.6k	1.8k	1.1k	359	21.8k
Ira M. Jacobson United States	64	17.0k 0.9×	15.7k 0.9×	3.0k 1.1×	1.5k 0.9×	962 0.9×	338	19.9k
Stanislas Pol France	71	15.1k 0.8×	14.2k 0.9×	3.1k 1.2×	1.2k 0.7×	898 0.8×	484	18.9k
Mark Sulkowski United States	72	22.5k 1.2×	20.6k 1.2×	6.2k 2.4×	1.6k 0.9×	899 0.8×	411	26.9k
Antonio Craxı̀ Italy	73	20.4k 1.1×	20.5k 1.2×	1.9k 0.7×	1.9k 1.1×	2.5k 2.3×	519	27.1k
Geoffrey Dusheiko United Kingdom	60	15.1k 0.8×	14.6k 0.9×	2.4k 0.9×	915 0.5×	605 0.6×	285	18.6k
David L. Thomas United States	72	21.7k 1.2×	21.0k 1.3×	4.2k 1.6×	1.5k 0.8×	873 0.8×	292	27.3k
Jean–Michel Pawlotsky France	82	19.7k 1.1×	17.6k 1.1×	3.5k 1.3×	1.9k 1.1×	719 0.7×	467	24.6k
Thomas Berg Germany	73	20.3k 1.1×	20.4k 1.2×	3.2k 1.2×	1.3k 0.7×	1.9k 1.8×	726	28.1k
Eugene R. Schiff United States	78	22.8k 1.2×	22.5k 1.4×	3.2k 1.2×	1.3k 0.8×	2.7k 2.5×	372	28.9k
Janice K. Albrecht United States	48	23.6k 1.3×	21.7k 1.3×	2.9k 1.1×	2.5k 1.4×	396 0.4×	117	26.0k

Countries citing papers authored by Stuart C. Gordon

Since Specialization

Citations

This map shows the geographic impact of Stuart C. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart C. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart C. Gordon more than expected).

Fields of papers citing papers by Stuart C. Gordon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart C. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart C. Gordon. The network helps show where Stuart C. Gordon may publish in the future.

Co-authorship network of co-authors of Stuart C. Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart C. Gordon. A scholar is included among the top collaborators of Stuart C. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart C. Gordon. Stuart C. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gordon, Stuart C., Yueren Zhou, Talan Zhang, et al.. (2023). Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals. Journal of Viral Hepatitis. 30(6). 544–550. 5 indexed citations

Lü, Mei, Loralee B. Rupp, Sheri Trudeau, et al.. (2023). Persistent pruritus associated with worse quality of life in patients with chronic hepatitis. Liver International. 44(2). 577–588. 6 indexed citations

Kim, W. Ray, Laura Telep, Belinda Jump, et al.. (2022). Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Alimentary Pharmacology & Therapeutics. 55(7). 828–835. 8 indexed citations

Lim, Young‐Suk, Wai‐Kay Seto, Masayuki Kurosaki, et al.. (2022). Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. Alimentary Pharmacology & Therapeutics. 55(8). 921–943. 19 indexed citations

Younossi, Zobair M., Kathleen E. Corey, Naim Alkhouri, et al.. (2020). Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices. Alimentary Pharmacology & Therapeutics. 52(3). 513–526. 62 indexed citations

González, Humberto C., Zaid Imam, Robert J. Wong, et al.. (2020). Normal alkaline phosphatase levels are dependent on race/ethnicity: National Health and Nutrition Examination Survey data. BMJ Open Gastroenterology. 7(1). e000502–e000502. 10 indexed citations

Gordon, Stuart C., Kuan-Han Wu, Keith D. Lindor, et al.. (2020). Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. The American Journal of Gastroenterology. 115(2). 262–270. 16 indexed citations

Lawitz, Eric, Fred Poordad, Leah J. Anderson, et al.. (2019). Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis. 26(6). 675–684. 5 indexed citations

Younossi, Zobair M., Maria Stepanova, K. Rajender Reddy, et al.. (2018). Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C. Liver International. 39(1). 54–59. 24 indexed citations

10.

Poordad, Fred, Stanislas Pol, Armen Asatryan, et al.. (2017). Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Hepatology. 67(4). 1253–1260. 105 indexed citations

11.

Jafri, Syed‐Mohammed & Stuart C. Gordon. (2015). The safety of daclatasvir for the treatment of hepatitis C. Expert Opinion on Drug Safety. 14(11). 1787–1797. 3 indexed citations

12.

Saab, Sammy, et al.. (2014). Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary Pharmacology & Therapeutics. 40(6). 657–675. 52 indexed citations

13.

Fung, Scott, Stuart C. Gordon, Zahary Krastev, et al.. (2014). Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log₁₀ copies/ml). Liver International. 35(2). 422–428. 4 indexed citations

14.

Gordon, Stuart C., Fayez M. Hamzeh, Paul J. Pockros, et al.. (2013). Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Alimentary Pharmacology & Therapeutics. 38(7). 784–793. 19 indexed citations

15.

Gordon, Stuart C., Eric M. Yoshida, Eric Lawitz, et al.. (2013). Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Alimentary Pharmacology & Therapeutics. 38(1). 16–27. 17 indexed citations

16.

Clark, Paul J., Alexander Thompson, Stuart C. Gordon, et al.. (2011). PREDICTORS OF CONSENT TO PHARMACOGENOMICS TESTING IN THE IDEAL STUDY. Hepatology. 54.

17.

Ghalib, R., E. Läwitz, B. Freilich, et al.. (2007). [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA. Journal of Hepatology. 46. S245–S246. 7 indexed citations

18.

Galan, Mark V., et al.. (2005). The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].. PubMed. 39(1). 64–7. 52 indexed citations

19.

Pianko, Stephen, John G. McHutchison, Stuart C. Gordon, et al.. (2002). Hepatic Iron Concentration Does Not Influence Response to Therapy with Interferon Plus Ribavirin in Chronic HCV Infection. Journal of Interferon & Cytokine Research. 22(4). 483–489. 21 indexed citations

20.

Gordon, Stuart C. & J. A. T. Woodford. (1986). The control of the clay-coloured weevil (Otiorhynchus singularis) (Coleoptera: Curculionidae) in raspberry in Eastern Scotland.. Crop Research. 26(2). 111–119. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact